By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell’s international commercialization strategy for its oncology and bone health portfolio.
Deal Structure & Product Portfolio
| Aspect | Detail |
|---|---|
| Licenser | Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) |
| Licensee | Undisclosed strategic partner in Malaysia |
| Products | Rexeva (Prolia biosimilar) & Denosu (Xgeva biosimilar) |
| Mabwell Responsibilities | Product development, manufacturing, and commercial supply |
| Partner Responsibilities | Local registration and sales in Malaysia |
Asset Profiles & Chinese Approvals
- Denosu (Xgeva biosimilar):
- Approved in China: March 2024.
- Indication: Treatment of unresectable giant cell tumor of bone or cases where surgery may cause severe functional impairment in adults and skeletally mature adolescents.
- Significance: The first Xgeva knock-off approved in China.
- Rexeva (Prolia biosimilar):
- Approved in China: April 2023.
- Indication: Treatment of osteoporosis in postmenopausal women at risk of fracture.
- Significance: The second Prolia copycat to gain global approval.
Strategic Rationale
This partnership leverages Mabwell’s robust biosimilar development and manufacturing capabilities with its partner’s established regulatory and commercial infrastructure in the Malaysian market. It provides Mabwell with a capital-efficient pathway to expand its geographic footprint in Southeast Asia without building a dedicated local sales force.
The move also validates the quality and regulatory standing of Mabwell’s biosimilar platform, as both products have already secured approval from China’s stringent NMPA. Access to the Malaysian market represents an important foothold for further expansion across the ASEAN region.
Forward-Looking Statements
This brief contains forward-looking statements regarding the regulatory and commercial success of Rexeva and Denosu in Malaysia. Actual results are subject to local regulatory approvals, market access, and competitive dynamics.-Fineline Info & Tech